A clinical trial with osimertinib in combination with a CDK 4/6 inhibitor in a population with EGFR mutated NSCLC with or without T790M is evaluating the efficacy of this combination; however, this trial excludes patients who previously received osimertinib [124]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.